StockWireNews
Low Float Nasdaq Idea (MYNZ) Could Have Cancer Quaking In Its Boots (5 Potential Catalysts To Know)
June 6th
Greetings Readers,
Let's dig in because this could get juicy.
Previously, when looking for Nasdaq, low float profiles, I came across this killer back in 2021.
Arriving the morning of 12/8/21, this profile took charge from an $8.55 open that day to a high of $30.00 by 1/18/22.
Running approximately 250% in just over a month, we crowned another champ.
But, that wasn't the last time you saw this idea.
This company went back on alert on 2/4/22. That day it opened at $13.67 and blazed to an $18.63 high on 2/17/22.
Boom. Another 36% (approx.) in 2 weeks.
And when you factor in the profiles I've brought to your attention over the past two weeks, we've been on quite a roll.
- 5/24's Profile - Ran approximately 76% over 2 days from a $.71 open to a $1.25 high.
- 5/26's Profile - Hit an almost 2-month high and ran approximately 15% intraday from a $1.29 open to a $1.49 high.
- 6/1's Profile - Displayed a strong showing over 2 days with an approximate 12% run from a $.90 open to a $1.01 high.
But that was then. This is now.
Once again, Mainz BioMed (NASDAQ: MYNZ) requires your immediate attention. Here's why...
Key MYNZ Potential Catalysts To Know
No. 1 - Low Float Profile
No. 2 - "A Significant Milestone And Achievement"
No. 3 - Game-Changing Partnership Announced
No. 4 - Multiple Pre-Clinical Milestones Achieved
No. 5 - Q1's Numerous Highlights And Results
But more on those in a second...
Cancer: What The Heck Are We Going To Do?
Cancer screening. None of us want to go through it, but make no doubt about it. It can be a life saver.
That said, with it comes the potential for a giant market.
Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%. (1)
Recent FDA decisions suggest that screening should be conducted once every three years starting at age 45.
Currently, there are 112 Million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. (1)
To dive in a little deeper, check out these stats: (1)
- 19 million Colonoscopies each year in USA
- ~38.8% Age 50 to 75 have never been screened (in USA)
- $3.7Bn Market Opp.
- 52,980 Expected deaths in US, 2021
Like I said, potential for a giant market.
Patients with cancers and other conditions are living longer and enjoying better health because of medical revolutions in diagnostic technology.
At its center are genetic and genomic tests that identify the unique genetic profile of individual patients or their disease and allow physicians to tailor treatment to those unique characteristics.
Mainz BioMed (NASDAQ: MYNZ) develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.
Mainz Biomed is located just west of Frankfurt in a world-renowned community for advanced DNA & Pharmaceutical research, including the home of vaccine maker BioNTech SE.
The company has historical research & development collaborations with major universities, laboratories and governments across Europe.
MYNZ's Flagship Product - ColoAlert(2)
ColoAlert detects tumors better than the standard test (FIT)
- Higher patient acceptance than FIT test.
- Accurate, non-invasive, simple, safe diagnostic solution to increase patient compliance.
- Proposed partnerships with clinical labs aims to speed test collection & results
- Designed to offer significant advantages compared to our major competitors
- Colorectal Cancer is the #2 leading killer (men & women combined)
- 52,980 deaths due to CRC in USA (2021)
- 5-year survival rate >90% (If detected at stage A).
How does ColoAlert work?
Early detection of colorectal cancer through tumor DNA analysis
Colorectal cancer originates from the genetic mutation of intestinal cells. These are continuously excreted through the stool and can be examined for tumor DNA using modern genetic diagnostic methods. ColoAlert analyzes samples for the following tumor markers:
- KRAS-mutation
- BRAF-mutation
- total amount of human DNA
- occult blood
These tumor markers can be associated with the occurrence of cancer.
How precise is ColoAlert?
Clinical studies confirm the advantages of tumor DNA analysis
In a multicentric study, a total of 566 patients were examined simultaneously using the occult blood test, M2-PK test and ColoAlert. All methods were also compared with the colonoscopy.
With a sensitivity of 85% and a specificity of 92%, ColoAlert showed the most accurate test results among the non-invasive screening methods.
Read the publication here.
-----
Major Market Opp. #2 - Commercial Pipeline Development – Future Product PancAlert (2)
- As GenX individuals age into their 40's and 50's they become part of the age group recommended to begin testing for CRC and more.
- Mainz BioMed is currently developing proprietary genetic testing methods for pancreatic cancer.
- Fighting what could soon become the world’s second most deadly cancer.
- Convenient stool test for at-home use.
- Potential for over 50 million tests per year in Europe alone.
- Supported by federal grant from Germany’s Federal Ministry for Education and Research.
- Cost of goods sold (COGS) & reimbursement analogous to ColoAlert program.
-----
And right now, due to several potential catalysts, MYNZ should hold the top spot on your watch-list. Here's what you need to know...
No. 1 MYNZ Potential Catalyst - Low Float Profile
According to the Yahoo Finance website, MYNZ has a low float.
The website reports this profile to have approximately 10.03Mn in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.
-----
No. 2 MYNZ Potential Catalyst - "A Significant Milestone And Achievement"
Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance
New and stringent EU regulation on in vitro diagnostic medical devices sets a higher standard of quality and safety for in vitro diagnostic (IVD) products and manufacturer process
BERKELEY, Calif. and MAINZ, Germany, June 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has successfully completed the conformity assessment of its internal processes to In Vitro Diagnostic Devices Regulation (IVDR) compliance which becomes mandatory from May 26, 2022. Additionally, the ColoAlert patient kit is now CE marked to the IVDR requirements, a significant milestone and achievement for the company. The new, harmonized IVDR regulatory framework has been established to ensure the safety and performance of in-vitro diagnostic medical devices in the European market. Meeting conformity assessment requirements to IVDR compliance for ColoAlert, Mainz Biomed’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC), involves meeting new standards for the CE mark of its stool collection tool.
“As a fast-growing organization and one looking to steadily unlock new global markets, it’s essential that we have watertight compliance across EU and other key jurisdictions,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The new IVDR framework is a major revision, focusing on patient safety and increasing the emphasis on the life-cycle management and continuous evaluation of products in the European market. While it significantly increases the regulatory burden for IVD manufacturers like ourselves, with the deep expertise of our team and existing sophistication of our internal processes and ColoAlert product, we’ve been able to successfully meet all the required criteria for compliance effectively and efficiently and in good time to meet the May 26th, 2022 deadline.”
Read the full article here.
-----
No. 3 MYNZ Potential Catalyst - Game-Changing Partnership Announced
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
- Dante Labs is a Global Leader in Genomics and Precision Medicine
- Mainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer
BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC).
Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals. Inherent to Dante Lab’s business model is managing state-of-the-art genomic sequencing laboratories in multiple international regions, and operating a robust e-commerce platform.
“As a young company with the goal of bringing to market important diagnostic tools to help treat and prevent cancer indications, it’s an absolute pleasure to partner with an industry leader such as Dante Labs,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Our differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility requires alliances with like-minded companies such as Dante Labs, who share our passion for forward-thinking diagnostic test development and marketing strategies.”
The partnership will first launch ColoAlert in Italy and UAE using Dante’s various established commercial channels. Samples will initially be processed at Mainz’s in-house facility and then Dante will purchase Mainz’s CE-IVD polymerase chain reaction (PCR) assay kits and transition all test processing to Dante’s wholly-owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) to offer localized service and support.
“We are excited by the opp. to align with Mainz and represent ColoAlert in these initial markets,” commented Andrea Riposati, Chief Executive Officer of Dante Labs. “Both the product and the Company mirror our mission to develop and market top-tier preventive health solutions and use new channels to make innovative tests available to more patients around the world. With the launch of our enhanced ecommerce platforms for advanced diagnostics, ColoAlert is an a-mazing product to deliver more personalized medicine.”
ColoAlert is currently marketed across Europe, and the partnership with Dante Labs marks the test’s initial launch in the Middle East. Mainz will continue to develop commercial and R&D partnerships with companies that lead the field of health screening with a particular focus on stool diagnostics.
Read the full article here.
-----
No. 4 MYNZ Potential Catalyst - Multiple Pre-Clinical Milestones Achieved
Mainz Biomed Provides Product Development Update on PancAlert
- Novel Screening Test for Pancreatic Cancer Funded by the German Government
- Achieved Key Project Milestones; Next Phase of Development Launched
BERKELEY, Calif. and MAINZ, Germany, May 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that PancAlert, its screening test candidate for pancreatic cancer has achieved multiple pre-clinical milestones that support the development of this potential first-in-class diagnostic for a deadly cancer indication.
...
Mainz Biomed is pleased to report the achievement of multiple predefined milestones for the PancAlert project, including achievement of specificity target, collection of a set of characterized clinical samples, selection of potential biomarker candidates, and the development of prototype biomarker tests. The Company will now allocate resources over the next 12 months to determine if the product candidate warrants clinical evaluation. It's possible that PancAlert’s technical profile will include functioning as a stool-based test, mirroring the Company’s flagship product ColoAlert, a highly efficacious and easy to use at-home detection test for colorectal cancer. However, given the growing understanding of the role of the microbiome in pancreatic cancer, Mainz Biomed will evaluate Real-Time Polymerase Chain Reaction (“PCR”)-based multiplex detection of molecular-genetic biomarkers and other testing methods in stool samples, and will also evaluate other collection methodologies including saliva, urine and blood.
“The composite of PancAlert’s project accomplishments is an important value inflection point for the test’s development as the data and material generated meet the threshold required to deploy resources to define the technical profile of this potentially game-changing diagnostic test for this deadly form of cancer where early detection plays an integral role in survival,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “All of us at Mainz are excited by the possibility to enhance our product pipeline with another cutting-edge diagnostic solution, and we extend our gratitude to the German government for their support in incubating this important project.”
...
Read the full article here.
-----
No. 5 MYNZ Potential Catalyst - Q1's Numerous Highlights And Results
Mainz Biomed Announces First Quarter 2022 Results
BERKELEY, Calif. and MAINZ, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today operational results for the first quarter ended March 31, 2022.
Key Highlights
- Continued to ramp up EU commercial activities for ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer
- Acquired portfolio of novel mRNA biomarkers to potentially upgrade ColoAlert’s technical profile to achieve “gold standard” status for CRC at-home testing
- Commenced international clinical study (ColoFuture) to evaluate integration of these biomarkers into ColoAlert
- Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial
- Formally initiated ColoAlert’s U.S. medical reimbursement process with the Centers for Medicare Services (CMS)
- Executed a $25.8Mn public follow-on offering
- Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization
“This past quarter has proven to be an excellent period of progress across commercial, corporate and product development fronts,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The entire Mainz team is excited by the rapid growth achieved to date and remains steadfast in our conviction to advance an ambitious yet balanced strategy to maximize ColoAlert’s potential in the marketplace, and to build our oncology-focused diagnostic franchise via a unique commercial model and robust technical approach to product development.”
...
Read the full article here.
-----
Nasdaq Profile Recap: Key MYNZ Potential Catalysts To Know
No. 1 - Low Float Profile
No. 2 - "A Significant Milestone And Achievement"
No. 3 - Game-Changing Partnership Announced
No. 4 - Multiple Pre-Clinical Milestones Achieved
No. 5 - Q1's Numerous Highlights And Results
-----
Coverage is officially reinitiated on MYNZ. When you have time later, do this: